SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Solid Biosciences Inc. (SLDB)

NEW YORK, March 15, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Solid Biosciences Inc. ("Solid" or the "Company") (NASADAQ: SLDB). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/sldb.

The investigation concerns whether Solid and certain of its officers and/or directors have violated Federal Securities Laws.

On March 14, 2018, post-market, Solid announced that the U.S. Food and Drug Administration has placed a clinical hold on Solid's study of SGT-001, a treatment for Duchenne muscular dystrophy, after a patient experienced an unexpected adverse reaction.  On this news, Solid's share price has fallen sharply during intraday trading on March 15, 2018.

If you are aware of any facts relating to this investigation, or purchased Solid shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/sldb. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC